AP NEWS

Dr. Reddy’s to Release Q2 FY19 Results on October 26, 2018

October 3, 2018

HYDERABAD, India--(BUSINESS WIRE)--Oct 3, 2018--Dr. Reddy’s Laboratories (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) will announce results for the quarter ended September 30, 2018 on Friday, October 26, 2018 after the Board Meeting.

Summary of Events

Earnings Call

Following the release, the management of the Company will host an earnings call to discuss the Company’s financial performance. (Dial In and other details given below)

Play Back

The play back will be available after the earnings call, through November 1st, 2018. For play back dial in phone No: 022 7194 5757 / 022 6663 5757, and Playback Code is 07565.

No password/pin number is necessary to dial in to any of the above numbers. The operator will provide instructions on asking questions before and during the call.

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddy’s operates in markets across the globe. Our Major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues.

The company assumes no obligation to update any information contained herein.

View source version on businesswire.com:https://www.businesswire.com/news/home/20181003005535/en/

CONTACT: Dr. Reddy’s Laboratories Ltd.

INVESTOR RELATIONS

SAUNAK SAVLA

+91-40-49002135

saunaks@drreddys.com

or

MEDIA RELATIONS

CALVIN PRINTER

+91-40-49002121

calvinprinter@drreddys.com

KEYWORD: ASIA PACIFIC INDIA

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Dr. Reddy’s Laboratories

Copyright Business Wire 2018.

PUB: 10/03/2018 09:42 AM/DISC: 10/03/2018 09:42 AM

http://www.businesswire.com/news/home/20181003005535/en

AP RADIO
Update hourly